London (UK) and Rehovot (Israel) June 27th, 2023
Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ).
The preliminary results on more than 50% of the planned number of patients in this rare disease shows a more than 50% overall response and more than 20% Complete Clearance in Cutaneous T Cell Lymphoma patients.
It is the first time that the original mode of action of Vidac Pharma drug shows a Clinical activity in a Human Lymphoma, confirming the multiple potential of its original mode of action. VDA 1102 reverses the Warburg effect returning cells to normal metabolism and positively modifying the Tumor Micro Environment (TME). What was until now a scientific concept clinically proven in humans only in the Squamous Cell Carcinoma spectrum (AK to SCC) is now demonstrated as a potential drug against Lymphoma a completely different type of cancer.
It is to be noted that while the product was still formulated for superficial epidermal carcinoma it is already as effective as other topical drugs against CTCL. "We are extremely encouraged by these preliminary results which are full of teaching for continuation of the Phase 2A and encourage us to develop a formulation more adapted to circulating Lymphoma T Cells which are expressed more in depth in the skin”, says Prof.
Dr Max Herzberg Chairman of Vidac Pharma. More detailed results will be presented at the HTID5 conference in Paris on 24-25th of October 2023 and in other scientific meetings when full patient enrollment will be achieved.
Rehovot (Israel) and London (UK)
About Vidac Pharma: Vidac Pharma Holdings Plc. London, is the holding company of Vidac Pharma Ltd. Rehovot. The Company is a clinical stage biopharmaceutical company dedicated to discovering and developing First-in-class medicines to help people suffering from a range of oncologic and dermatologic diseases.
The following information does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only.